Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation

[1]  W. Marston Linehan,et al.  Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors , 2011, PLoS genetics.

[2]  M. Yao,et al.  Copy number profiling in von hippel‐lindau disease renal cell carcinoma , 2011, Genes, chromosomes & cancer.

[3]  N. Rothman,et al.  Occupational trichloroethylene exposure and renal carcinoma risk: evidence of genetic susceptibility by reductive metabolism gene variants. , 2010, Cancer research.

[4]  Anjilna Wali.  FHIT Doubts are Clear Now , 2010, TheScientificWorldJournal.

[5]  W. Gregory,et al.  Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma , 2009, Clinical Cancer Research.

[6]  J. Gu,et al.  Genome‐wide profiling of chromosomal alterations in renal cell carcinoma using high‐density single nucleotide polymorphism arrays , 2009, International journal of cancer.

[7]  N. Rioux-Leclercq,et al.  Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma , 2009, British Journal of Cancer.

[8]  Arianna Di Napoli,et al.  Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. , 2009, Cancer research.

[9]  P Boffetta,et al.  Tobacco smoking, body mass index, hypertension, and kidney cancer risk in central and eastern Europe , 2008, British Journal of Cancer.

[10]  W. Chow,et al.  Contemporary Epidemiology of Renal Cell Cancer , 2008, Cancer journal.

[11]  S. Hirohashi,et al.  Genetic Clustering of Clear Cell Renal Cell Carcinoma Based on Array-Comparative Genomic Hybridization: Its Association with DNA Methylation Alteration and Patient Outcome , 2008, Clinical Cancer Research.

[12]  D. Aust,et al.  Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. , 2008, Neoplasia.

[13]  T. Choueiri,et al.  Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. , 2008, Future oncology.

[14]  W. Chow,et al.  Dietary risk factors for kidney cancer in Eastern and Central Europe. , 2007, American journal of epidemiology.

[15]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[16]  K. Chew,et al.  Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel‐Lindau gene status , 2006, BJU international.

[17]  Jane Fridlyand,et al.  Bioinformatics Original Paper a Comparison Study: Applying Segmentation to Array Cgh Data for Downstream Analyses , 2022 .

[18]  Joon-Oh Park,et al.  Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. , 2005, Oncology reports.

[19]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[20]  W. Marston Linehan,et al.  Genetic Basis of Cancer of the Kidney , 2004, Clinical Cancer Research.

[21]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[22]  Gordon K Smyth,et al.  Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.

[23]  W Marston Linehan,et al.  Genetic Basis of Cancer of the Kidney , 2006 .

[24]  Y. Pekarsky,et al.  FHIT: from gene discovery to cancer treatment and prevention. , 2002, The Lancet. Oncology.

[25]  Kazuki Kobayashi,et al.  VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. , 2002, Journal of the National Cancer Institute.

[26]  W. Kaelin,et al.  Molecular basis of the VHL hereditary cancer syndrome , 2002, Nature Reviews Cancer.

[27]  Ajay N. Jain,et al.  Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. , 2002, Cancer research.

[28]  Joe W. Gray,et al.  Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas , 2001, Nature Genetics.

[29]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[30]  W. Kuo,et al.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays , 1998, Nature Genetics.

[31]  T. Goodrow,et al.  The FHIT gene product is highly expressed in the cytoplasm of renal tubular epithelium and is down-regulated in kidney cancers. , 1997, The American journal of pathology.

[32]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[33]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[34]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.